StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Organic / Comparable Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

Latest, FY2025
20.5%
Period ended Dec 31, 2025
Change on a year earlier
-5.0 pts
25.5% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Organic / Comparable Sales Growth (%) (%)Year on yearSource
FY2025Dec 31, 202520.5%-5.0 ptsSEC Filing (0001628280-26-002982) ↗
FY2024Dec 31, 202425.5%+12.4 ptsSEC Filing (0001628280-25-002092) ↗
FY2023Dec 31, 202313.1%+10.2 ptsSEC Filing (0001628280-24-002009) ↗
FY2022Dec 31, 20222.9%-11.4 ptsSEC Filing (0001628280-23-001516) ↗
FY2021Dec 31, 202114.3%+33.3 ptsSEC Filing (0001104659-22-007648) ↗
FY2020Dec 31, 2020-19.0%-23.7 ptsSEC Filing (0001104659-21-007942) ↗
FY2019Dec 31, 20194.7%+5.0 ptsSEC Filing (0001104659-20-005717) ↗
FY2018Dec 31, 2018-0.3%-14.2 ptsSEC Filing (0001104659-19-002848) ↗
FY2017Dec 31, 201713.9%–SEC Filing (0001104659-18-003691) ↗

Cite this data

StockData. (2026). Abbott Laboratories Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Organic / Comparable Sales Growth (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-nm-yoy-org-intl

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.